Latest Articles

Publication Date
All News Scientific
The Role of Astaxanthin as an Antioxidant and Anti-Inflammatory Agent in Human Health: A Systematic Review.

This systematic review aimed to summarize the effects of astaxanthin (ASX) supplementation on oxidative stress, inflammation, and metabolic regulation in human studies. A systematic search was conducted in Scopus, Web …

Published: Jan. 9, 2026, midnight
Read Full Article
anti-inflammatory antioxidant astaxanthin oxidative stress
Will Schwab Fundamental Emerging Markets Equity stock outperform global peers - Trade Exit Report & Community Trade Idea Sharing - ulpravda.ru

Will Schwab Fundamental Emerging Markets Equity stock outperform global peers - Trade Exit Report & Community Trade Idea Sharing ulpravda.ru

Published: Jan. 8, 2026, 9:28 p.m.
Read Full Article
Why Is Acrivon Therapeutics Stock Falling Today? - Acrivon Therapeutics (NASDAQ:ACRV) - Benzinga

Why Is Acrivon Therapeutics Stock Falling Today? - Acrivon Therapeutics (NASDAQ:ACRV) Benzinga

Published: Jan. 8, 2026, 7:02 p.m.
Read Full Article
NEWS: NHS to Launch Online Hospital to Speed Up Specialist Care - Practice Business

NEWS: NHS to Launch Online Hospital to Speed Up Specialist Care Practice Business

Published: Jan. 8, 2026, 5:44 p.m.
Read Full Article
Dr. Jessica Ritch Opens EnRitched Gynecology, a New Membership-Based Women’s Health Practice - Rutland Herald

Dr. Jessica Ritch Opens EnRitched Gynecology, a New Membership-Based Women’s Health Practice Rutland Herald

Published: Jan. 8, 2026, 4:15 p.m.
Read Full Article
Can LakeShore Biopharma Co. Ltd Equity Warrant stock outperform in 2025 bull market - Weekly Trade Review & Daily Volume Surge Signals - ulpravda.ru

Can LakeShore Biopharma Co. Ltd Equity Warrant stock outperform in 2025 bull market - Weekly Trade Review & Daily Volume Surge Signals ulpravda.ru

Published: Jan. 8, 2026, 2:18 p.m.
Read Full Article
Acrivon's ACR-368 Shows 52% Response Rate In Endometrial Cancer, Expands Trial To Europe - Nasdaq

Acrivon's ACR-368 Shows 52% Response Rate In Endometrial Cancer, Expands Trial To Europe Nasdaq

Published: Jan. 8, 2026, 1:42 p.m.
Read Full Article
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 - The Manila Times

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 …

Published: Jan. 8, 2026, 12:53 p.m.
Read Full Article
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b - GlobeNewswire

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b GlobeNewswire

Published: Jan. 8, 2026, 12:30 p.m.
Read Full Article
Belfast: Man, 72, charged with rape and human trafficking - BBC

Belfast: Man, 72, charged with rape and human trafficking BBC

Published: Jan. 8, 2026, 12:10 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!